{
  "context": {
    "rules": [
      "Rule1: Either a safety issue for CompoundX was reported, or an adverse event study was conducted on CompoundX.",
      "Rule2: Should an adverse event study have been conducted on CompoundX, then it is the case that the availability of a generic version implies the patent for CompoundX has expired.",
      "Rule3: If the FDA is investigating CompoundX, then the availability of a generic version necessitates that the patent for CompoundX has expired.",
      "Rule4: Provided that a recall order was issued for CompoundX, it is not the case that a product recall occurred for CompoundX.",
      "Rule5: If a new formulation of CompoundX exists, then CompoundX has an extended release mechanism.",
      "Rule6: Should CompoundX have improved bioavailability, then CompoundX is on the market.",
      "Rule7: If CompoundX has an extended release mechanism, then CompoundX dosing has been reduced.",
      "Rule8: Under the condition that CompoundX dosing has been reduced, CompoundX has improved bioavailability.",
      "Rule9: If CompoundX was developed by LabAlpha, then CompoundX is patented.",
      "Rule10: Whenever a manufacturing upgrade was performed for CompoundX, CompoundX is on the market.",
      "Rule11: Should CompoundX be compliant with Good Manufacturing Practices (GMP), then CompoundX is on the market.",
      "Rule12: Under the condition that equipment modernization was undertaken for CompoundX, a manufacturing upgrade was performed for CompoundX.",
      "Rule13: Either equipment modernization was undertaken for CompoundX, or process automation was implemented for CompoundX.",
      "Rule14: If process automation was implemented for CompoundX, then a quality control system is in place for CompoundX.",
      "Rule15: Provided that a supply chain disruption affected CompoundX, a raw material shortage affected CompoundX.",
      "Rule16: If CompoundX is patented, then CompoundX had a successful clinical trial.",
      "Rule17: Either an import license was secured for CompoundX, or an alternative supplier was found, or a raw material shortage leads to a production delay when the product is not on the market.",
      "Rule18: Under the condition that a batch tracking system is in place for CompoundX, CompoundX is compliant with Good Manufacturing Practices (GMP).",
      "Rule19: Provided that software was implemented for CompoundX, then the implementation of process automation necessitates that a batch tracking system is in place.",
      "Rule20: Should hardware be installed for CompoundX, then the implementation of process automation implies a batch tracking system is in place.",
      "Rule21: Whenever a system integration failure occurred for CompoundX, data corruption occurred for CompoundX.",
      "Rule22: Under the condition that a validation error occurred for CompoundX, data corruption did not occur for CompoundX.",
      "Rule23: Should a contingency plan be activated for CompoundX, then either a backup supplier is available, or a supply chain disruption leads to a production delay if the product is not on the market.",
      "Rule24: If an emergency protocol was executed for CompoundX, then either a backup supplier is available, or a supply chain disruption necessitates a production delay when the product is not on the market.",
      "Rule25: Should a crisis management team be formed for CompoundX, management approval was obtained for CompoundX.",
      "Rule26: Either a crisis management team was formed for CompoundX, or an emergency response unit was deployed for CompoundX.",
      "Rule27: Provided that an emergency response unit was deployed for CompoundX, an emergency protocol was executed for CompoundX.",
      "Rule28: Under the condition that board authorization was obtained for CompoundX, a contingency plan was activated for CompoundX.",
      "Rule29: Should production of CompoundX be rescheduled, then production of CompoundX was delayed.",
      "Rule30: Provided that the timeline for CompoundX was adjusted, production of CompoundX was rescheduled.",
      "Rule31: If process validation is complete for CompoundX, then an alternative process is available for CompoundX.",
      "Rule32: Either process validation is complete for CompoundX, or a manual override was authorized for CompoundX.",
      "Rule33: Provided that a manual override was authorized for CompoundX, supervisor approval was obtained for CompoundX.",
      "Rule34: Either CompoundX was withdrawn from the market, or it is not the case that CompoundX received a regulatory rejection.",
      "Rule35: Either production of CompoundX was halted, or CompoundX was not withdrawn from the market.",
      "Rule36: If a manufacturing license was granted for CompoundX, then CompoundX is on the market.",
      "Rule37: If it is not the case that a reported safety issue leads to an FDA investigation, then a product recall occurred for CompoundX.",
      "Rule38: Provided that it is false that a quality control system implies GMP compliance, then a compliance failure occurred for CompoundX.",
      "Rule39: Under the condition that neither software was implemented nor hardware was installed for CompoundX, a system integration failure occurred for CompoundX.",
      "Rule40: If it is not the case that a system integration failure leads to a validation error, then validation was successful for CompoundX.",
      "Rule41: Should it be false that a system integration failure necessitates a validation error, then validation was not successful for CompoundX.",
      "Rule42: Whenever it is not the case that a successful clinical trial implies approval leads to the product being on the market, then CompoundX received a regulatory rejection.",
      "Rule43: Provided that it is false that management approval implies board authorization, then authorization was denied for CompoundX.",
      "Rule44: If it is not the case that either regulatory approval was received or authorization was not denied, then approval is pending for CompoundX.",
      "Rule45: Under the condition that it is false that regulatory approval was received or authorization was not denied, approval is not pending for CompoundX.",
      "Rule46: Should it be false that supervisor approval implies a supply chain disruption leads to a production delay when the product is not on the market, then an override was rejected for CompoundX.",
      "Rule47: Provided that it is not the case that supervisor approval necessitates a supply chain disruption causing a production delay without the product on the market, then an override was not rejected for CompoundX.",
      "Rule48: If a manufacturing license was not granted for CompoundX, then a generic version of CompoundX is available.",
      "Rule49: Provided that CompoundX is not on the market, the timeline for CompoundX was adjusted.",
      "Rule50: Under the condition that CompoundX is not on the market, it is not the case that production of CompoundX was delayed."
    ],
    "facts": [
      "Fact1: CompoundX is an approved compound.",
      "Fact2: A recall order was issued for CompoundX.",
      "Fact3: A new formulation of CompoundX exists.",
      "Fact4: CompoundX was developed by LabAlpha.",
      "Fact5: A supply chain disruption affected CompoundX.",
      "Fact6: A compliance failure did not occur for CompoundX.",
      "Fact7: An alternative supplier was not found for CompoundX.",
      "Fact8: An import license was not secured for CompoundX.",
      "Fact9: A backup supplier is not available for CompoundX.",
      "Fact10: Regulatory approval was not received for CompoundX.",
      "Fact11: An alternative process is not available for CompoundX.",
      "Fact12: Production of CompoundX was not halted.",
      "Fact13: The patent for CompoundX has not expired."
    ]
  },
  "question": "CompoundX is on the market."
}